⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 1, 2025

Table 4 from Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

Robert Wesolowski Hope S. Rugo Jennifer M. Specht Hyo S. Han Peter Kabos Ulka N. Vaishampayan Seth A. Wander Keerthi Gogineni Alexander I. Spira Anne F. Schott Maysa Abu‐Khalaf Sarah C. Mutka Samuel Suzuki Brian Sullivan Igor Gorbatchevsky Rachel M. Layman

View Full Paper

Ask AI

Bookmark

Share

Key Points

Combination therapy resulted in serious adverse events, impacting patient safety.
Grade 3 or 4 TESAEs occurred in more than one patient, affecting the safety profile of the treatment.
The study involved patients with advanced breast cancer who had not received prior systemic therapy.
Findings suggest the need for careful monitoring of side effects for this drug combination.

Implication

Clinical assessment of combination therapy in hormone receptor–positive, HER2-negative patients, highlighting serious adverse events.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wesolowski et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a219af https://doi.org/10.1158/1078-0432.30255508

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table 3 from Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer2025
2Table 1 from Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer2025
3Table 2 from Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer2025
4Figure 1 from Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer2025
5Figure 2 from Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer2025